Chief Operating Officer, Roivant Platforms
Matt Maisak serves as Chief Operating Officer, Roivant Platforms. Dr. Maisak joined the Roivant team in 2018. Prior to leading the Roivant Platforms, Dr. Maisak was a key member of the Axovant business development team, where he led the in-licensing efforts for the GM1 and GM2 gangliosidoses gene therapy programs from the University of Massachusetts. Prior to Roivant, Dr. Maisak held several strategic roles in Global Operations at Roche Diagnostics, where he worked across regulatory and manufacturing strategy.
Dr. Maisak earned a doctor of philosophy from the Max Planck Institute working under Dr. Alexander Borst. During this time, he investigated the role single neuronal subtypes play in the computation of direction selective motion vision. His work was published in Nature and Current Biology and featured in popular science media such as National Geographic (Geo) and Bayerischer Rundfunk. Dr. Maisak studied medicine at Yale University School of Medicine.